Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment sequence with romosozumab influences osteoporosis outcomes

Key clinical point: Using anabolic agents up front is associated with better bone mineral density outcomes and improved bone-turnover markers.

Major finding: Giving romosozumab for 1 year before an antiresorptive improved bone mineral density and bone turnover markers.

Study details: Review of four published clinical trials on romosozumab and other agents for osteoporosis.

Disclosures: The study was sponsored by Amgen, UCB, and Astellas. Dr. Cosman disclosed grants/research support from Amgen, and consulting fees and speaker activities for Amgen and Radius Health. Dr. Bolster disclosed relationships with Cumberland, Corbus, Gilead, Johnson & Johnson, AbbVie, and Pfizer.


Cosman F et al. Arthritis Rheumatol. 2020;72(suppl 10), Abstract 1973